Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Italy
  4. Borsa Italiana
  5. LIFE CARE
  6. News
  7. Summary
    LCC   IT0005323560

LIFE CARE

(LCC)
SummaryQuotesChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Biogenera S.p.A. cancelled the acquisition of Life Care Capital S.p.A. in a reverse merger transaction.

06/30/2020 EDT

Biogenera S.p.A. signed a frame work agreement to acquire Life Care Capital S.p.A. (BIT:LCC) €70 million in a reverse merger transaction on February 21, 2020. For each LCC ordinary share will be allocated from a minimum of 0.8282 Biogenera ordinary share (in case of payment of the Extraordinary Dividend and without any exercise of the Right of withdrawal mentioned below) to a maximum of 1.0607 ordinary share of Biogenera (in case of exercise of the Right of Withdrawal involving the redemption or cancellation by the Company of a number of shares equal to 30% minus 1 share and the absence of any payment of the Extraordinary Dividend); ii. no. 1 Biogenera special share will be allocated for each LCC special share, also due to the fact that it is envisaged that holders of LCC special share will not receive the Extraordinary Dividend mentioned above and that post-Merger Biogenera special share will continue to benefit from the current 1:6 conversion ratio into ordinary shares. Finally, the Merger Plan envisaged that for each LCC warrant will be allocated 1 Biogenera warrant. The first Board of Directors of the company resulting from the Merger will be of 9 directors, including (i) 6 directors upon designation of the Promoters of LCC, including Alessandra Gavirati (as Chairman), Luigi Colombo (as Chief Operating Officer) and Alessandro Piga; (ii) 2 directors upon designation of Founding Members, in the persons of Andrea Pession (as Vice Chairman, Chief Medical Officer and Chief Scientific Officer) and Stefano Biondi; and (iii) one independent director. The company resulting from the Merger will execute a directorship agreement with Andrea Pession, who will act as Vice Chairman, Chief Medical Officer and Chief Scientific Officer. The ordinary shares and warrants of the company resulting from the Merger will be listed on the AIM Italia. The deal is subject to approval by shareholders of Biogenera S.p.A. and Life Care Capital S.p.A by June 2020. The Board of Directors of Life Care Capital approved the transaction on February 24, 2020. The Board of Directors of Life Care Capital and Biogenera S.p.A approved the transaction on May 22, 2020. The merger deed will be signed on end of July 2020.The shareholders of Life Care did not approve the transaction. Equita SIM S.p.A and Deloitte & Touche acted as financial advisors, Chiomenti acted as legal advisor, Spada Partners acted as accountant, Marchi & Partners acted as intellectual property due diligence advisor and LC Consulting and Fondazione Charta for the business due diligence advisor for Life Care Capital. Alantra acted as financial advisor and Carnelutti acted as legal advisor for Biogenera. Biogenera S.p.A. cancelled the acquisition of Life Care Capital S.p.A. (BIT:LCC) in a reverse merger transaction on June 30, 2020.


© S&P Capital IQ 2020
All news about LIFE CARE
2020Biogenera S.p.A. cancelled the acquisition of Life Care Capital S.p.A. in a reverse mer..
CI
2020Biogenera S.p.A. signed a frame work agreement to acquire Life Care Capital S.p.A. for ..
CI
2018Life Care Capital S.p.A. has completed an IPO in the amount of €140 million.
CI
2018Life Care Capital S.p.A. has filed an IPO.
CI
More news
Financials
Sales 2019 - - -
Net income 2019 -0,51 M -0,60 M -0,60 M
Net cash 2019 142 M 165 M 165 M
P/E ratio 2019 -273x
Yield 2019 -
Capitalization 142 M 169 M 166 M
EV / Sales 2018 -
EV / Sales 2019 -
Nbr of Employees -
Free-Float 97,9%
Chart LIFE CARE
Duration : Period :
LIFE CARE Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Alessandra Gavirati Chief Executive Officer & Director
Carlo Castellano Chairman
Alberto Dalmasso Independent Director
Giovanni Jody Vender Director
Luigi Sala Director
Sector and Competitors
1st jan.Capi. (M$)
LIFE CARE1.53%169
INVESTOR AB (PUBL)33.22%71 170
CK HUTCHISON HOLDINGS LIMITED-2.13%26 133
GROUPE BRUXELLES LAMBERT SA20.36%17 534
HAL TRUST29.36%15 023
AB INDUSTRIVÄRDEN (PUBL)4.74%14 424